Skip to main content
OpenTrials
Completed

NCT Number: NCT00687414

Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders

Aim of the study is to analyze the expression of genes and sequences encoding the human mammalian diaphanous (mDia) related formin proteins to test the hypothesis that defects in the mDia expression or function might drive the pathophysiology of myelodysplastic syndrome, acute myeloid leukemia and other myeloproliferative diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myeloproliferative Disorder AML Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases MDS Myeloproliferative Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St Mary's Health Care, Grand Rapids, Michigan, United States

Loading trial locations.

About this study

Leukocytes and myeloid lineage cells from these specimens will be assayed for expression of DRF genes using standard molecular biological approaches to measure mRNA levels. Extracted DNA will be analyzed for mutations that affect expressions or function using direct sequencing techniques.

Alternatively, expression of DRF gene products (mDia proteins) will be assessed using specific antibodies and flow cytometry. Molecular findings resulting from these assays will be correlated with clinical information recorded in specimen logbook.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 and over
  • Male
  • Female
  • Diagnosed with MDS, MPD and AML

Exclusion criteria

  • Under the age of 18
  • Received bone marrow transplant

Control Group Criteria:

inclusion:

  • healthy men and women
  • ≥ 55 years of age

exclusion:

  • history of hematological condition
  • history of cancer

Treatment and study plan

Primary outcomes

  1. to determine if defective DRF1 expression or mDia1 function may contribute to myeloid malignancies and point to mDia1 as an attractive therapeutic target in MDS and MPS

    Time frame: within a year

Sponsors and collaborators

Lead sponsor

Corewell Health West

Other

Collaborators

  • Community Foundation for Southeast Michigan (JP McCarthy Fund)
  • Van Andel Research Institute

Registry information

Important dates

Study start
2008
Primary completion
2009
Study completion
2010
First posted
May 30, 2008
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.